Retrophin is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases. Retrophin (NASDAQ:RTRX) is a fully-integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”RTRX” api=”yf” style=”font-size: 15px”]
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/retrophin” connections=”true” suffix=””]
In Oct. 2014, Retrophin, divest non-core assets ketamine, Syntocinon Nasal Sprayë (oxytocin), and Vecamylë (mecamylamine HCI tablets) to Turing Pharmaceuticals for a $3 Mn upfront payment. Turning is developing intranasal formulation of ketamine for a variety of psychiatric indications.